ONCODESIGN PRECISION MEDICINE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.015 EUR | +1.50% |
|
+6.84% | -43.92% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -43.92% | 19.96M | - | ||
| +18.97% | 45.34B | B- | ||
| +41.98% | 40.42B | A | ||
| -10.06% | 37.92B | B | ||
| +31.15% | 31.75B | B | ||
| -7.79% | 27.71B | C | ||
| +13.32% | 26.52B | B- | ||
| +43.05% | 13.96B | B+ | ||
| +31.28% | 12.44B | C+ | ||
| -7.41% | 11.26B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ALOPM Stock
- Ratings Oncodesign Precision Medicine
